Location History:
- Berkeley, CA (US) (1994 - 1996)
- Oakland, CA (US) (2000 - 2013)
- Guilford, CT (US) (2013 - 2023)
Company Filing History:
17 out of 15,475 
2 out of 48 
2 out of 1,327 
Years Active: 1994-2023
Title: Jonathan A. Ellman: Innovator in Pharmaceutical Patents
Introduction
Jonathan A. Ellman, based in Oakland, CA, is an accomplished inventor with a remarkable portfolio of 19 patents. His groundbreaking work primarily focuses on small-molecule inhibitors and their therapeutic applications, particularly in the realm of cancer and metabolic disorders.
Latest Patents
Among his latest innovations are novel compounds aimed at treating severe health conditions. One key patent involves small-molecule PI5P4K alpha/beta inhibitors, which disclose the discovery of unique 2-amino-dihydropteridinone compounds capable of inhibiting phosphatidylinositol phosphate kinases. These compounds offer promising avenues for treating p53-null cancer and metabolic disorders such as type 2 diabetes and obesity. Additionally, Ellman holds a patent for compounds and compositions intended for treating fibrosis, offering methods to alleviate diseases modulated by MKP-5.
Career Highlights
Ellman has been associated with reputable institutions, significantly contributing to research and innovation in the pharmaceutical sector. He has worked with the University of California and the Buck Institute for Research on Aging, where his expertise has fostered advancements in health-related technologies.
Collaborations
In his career, Jonathan has collaborated with notable professionals, including Ingrid Choong and Fanqing Frank Chen. These partnerships have further enriched his research endeavors and have been pivotal in the successful development of his patented inventions.
Conclusion
Jonathan A. Ellman's contributions to the field of pharmaceuticals through his patents highlight his commitment to advancing healthcare solutions. His innovative work, particularly in addressing cancer and metabolic disorders, underscores the importance of continued research and development in improving patient outcomes.